Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. By leveraging genetic insights, Praxis aims to address conditions ranging from major depressive disorder to epilepsy.
The company's lead product candidates include:
- Prax-114: An extrasynaptic-preferring GABAA receptor positive allosteric modulator, currently in Phase IIa trials for treating major depressive disorder and perimenopausal depression.
- Prax-944: A selective small molecule inhibitor of T-type calcium channels, in Phase IIa trials for essential tremor treatment.
- Prax-562: A persistent sodium current blocker in Phase I trials aimed at severe pediatric epilepsy and adult cephalgia.
- Prax-222 (Elsunersen): An antisense oligonucleotide targeting gain-of-function SCN2A epilepsy, under collaboration with Ionis Pharmaceuticals and RogCon, Inc.
- PRAX-628: A next-gen small molecule targeting sodium-channels in the brain, being developed as a treatment for focal epilepsy.
- Ulixacaltamide: A small molecule inhibitor for essential tremor, currently in late-stage development.
Recent news highlights include a partnership with Tenacia to extend ulixacaltamide's reach to Greater China, and advances in the PRAX-628 program demonstrating its potential as a best-in-class epilepsy drug.
Financially, Praxis has shown significant progress. As of the latest reports, the company has sufficient funding to continue operations into 2027, driven by strategic public offerings and a lean operational model.
For more details, visit www.praxismedicines.com and follow them on social media channels.
Rhea-AI Summary
Praxis Precision Medicines to present data from its clinical-stage epilepsy programs at the 35th International Epilepsy Congress. Phase 1 study of PRAX-628 shows a potentially best-in-class safety profile for focal epilepsy. PRAX-562 program shows broad anticonvulsant activity in multiple DEE mouse models. Positive impact on stock price expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.76%
Tags
-
Rhea-AI Summary
Praxis Precision Medicines to present analyses from its Essential1 study of ulixacaltamide at MDS Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) reported a corporate update and financial results, with $124.3 million cash as of June 30, 2023. The company is on track to initiate Phase 3 studies for ulixacaltamide in Q4 2023 after a favorable End-of-Phase 2 meeting with FDA. The PRAX-628 Phase 1 study showed consistent safety profile and target engagement in measures of qEEG activity at all doses with first administration. The company plans to hold an R&D Portfolio Day on October 2 to elaborate on their science and clinical progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
Rhea-AI Summary
Praxis Precision Medicines, Inc. (PRAX) announced positive data from the Essential1 study for ulixacaltamide, a potential therapy for Essential Tremor. Patients dosed with ulixacaltamide for up to 14 weeks showed maintained or improved efficacy results, while those withdrawing to placebo experienced worsening. The sub-study execution confirmed design features for the upcoming Phase 3 program expected to initiate in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
-
News
Rhea-AI Summary
PRAX-628 Phase 1 study shows pharmacodynamic activity across all dose levels compared to placebo. PRAX-628 expected to be best-in-class treatment for focal epilepsy. Phase 2 PPR study results to be announced later this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. announces the pricing of its public offering of common stock and pre-funded warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.23%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.23%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
FAQ
What is the current stock price of Praxis Precision Medicines (PRAX)?
The current stock price of Praxis Precision Medicines (PRAX) is $76.52 as of December 20, 2024.
What is the market cap of Praxis Precision Medicines (PRAX)?
The market cap of Praxis Precision Medicines (PRAX) is approximately 1.4B.
What does Praxis Precision Medicines, Inc. specialize in?
Praxis specializes in developing therapies for CNS disorders characterized by neuronal imbalance, leveraging genetic insights for innovative treatments.
What are the primary product candidates of Praxis?
Praxis' key product candidates include Prax-114, Prax-944, Prax-562, Prax-222 (Elsunersen), PRAX-628, and Ulixacaltamide.
What is the status of Prax-114?
Prax-114 is in Phase IIa clinical trials for the treatment of major depressive disorder and perimenopausal depression.
How is Praxis advancing its epilepsy treatments?
Praxis is developing PRAX-562 and PRAX-628, with the latter showing strong potential as a best-in-class focal epilepsy treatment.
What are recent corporate milestones for Praxis?
Recent milestones include strategic partnerships, ongoing clinical trials, and financial progress ensuring operations funding into 2027.
Can you provide financial details on Praxis' operations?
As of the latest reports, Praxis has $243.3 million in cash, cash equivalents, and marketable securities, with funding expected to last into 2027.
How can I stay updated on Praxis' developments?
Visit https://www.praxismedicines.com and follow them on Facebook, LinkedIn, and Twitter/X for the latest updates.
What partnerships has Praxis recently announced?
Praxis recently partnered with Tenacia to extend ulixacaltamide's reach to Greater China and continues collaborations with Ionis Pharmaceuticals and RogCon, Inc.
What is Ulixacaltamide, and what is its current development stage?
Ulixacaltamide is a selective small molecule inhibitor for essential tremor, currently in late-stage development.
Where can I find more information about Praxis' clinical studies?
You can learn more about Praxis' clinical studies on their official website, www.praxismedicines.com, and specific study sites like www.praxisessentialtremor.com.
Praxis Precision Medicines, Inc.
Nasdaq:PRAX
PRAX Rankings
PRAX Stock Data
1.37B
17.35M
0.25%
103.96%
8.2%
Biotechnology
Pharmaceutical Preparations
United States of America
BOSTON